Image

Global Soft Tissue Sarcoma Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Soft Tissue Sarcoma Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Soft Tissue Sarcoma Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 3,426.71 Million
Diagram Market Size (Forecast Year) USD 6,295.77 Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Soft Tissue Sarcoma Market, By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Soft Tissue Sarcoma Market

Soft Tissue Sarcoma Market Analysis and Size

The global soft tissue sarcoma market is expected to witness significant growth during the forecast period. Sarcomas account for less than 1.0% of all adult cancers. Over 65% of the major drugs have been developed or are being developed for administration through the oral route. Particularly, around 60% of the soft tissue sarcoma targeting therapeutics have been developed for use as the 1st line of treatment.

Data Bridge Market Research analyses a growth rate in the global soft tissue sarcoma market in the forecast period 2022-2029. The expected CAGR of global soft tissue sarcoma market is tend to be around 7.9% in the mentioned forecast period. The market was valued at USD 3426.71  million in 2021, and it would grow upto USD 6295.77 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Soft Tissue Sarcoma Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland)

Market Opportunities

  • Introduction of many therapies
  • Rising Healthcare Awareness
  • Increase in Partnerships

Market Definition

Liposarcoma is a type of soft tissue sarcoma wherein cancer originates from the fat cells in soft tissue present in the skin's middle and outer layers. It is caused either by genetic factor, radiation treatment or maybe others idiopathic reasons. Liposarcoma can be of four types: myxoid liposarcoma, pleomorphic liposarcoma, well-differentiated liposarcoma,  and dedifferentiated liposarcoma. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Soft Tissue Sarcoma Market Dynamics

Drivers

  • Increase in Cancer Cases

According to the WHO 2016, liposarcoma is the most common type of sarcomas and is classified as a rare disease, accounting for about 17-20% of all sarcoma cases. According to the report published by the Genetics Education Center, University of Kansas Medical Center, about 15% of all the cancers have an inherited susceptibility and almost 12% of the hospital admissions in the U.S. accounted for the treatment of genetic causes in 2013. This boost the market growth.

  • Rising Involvement of Clinical Trials

Heavy unmet needs within the market present a main opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the rest in Phase I and Pre-clinical trials. The probable role for use of immuno-oncology agents in sarcomas is presently under evaluation in Phase I/II clinical trials. Thus, all these initiatives increase the market growth.

Opportunities

  • Increase in Partnerships

Around 80% of the reported deals were established in the past three years, with the majority being reported in 2020. The maximum of the instances were licensing agreements (45%). Additionally, more than 50% of the agreements were signed for therapeutics targeting liposarcoma. Thus, all these partnerships create much opportunities for the market growth.

  •  Introduction of many therapies

For more than 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. Although, even after complete surgical resection, around 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The establishment of targeted therapy has revolutionized the treatment model for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a crucial role in the growth of the market during the forecast period.

  • Rising Healthcare Awareness

Awareness among patients as well as healthcare providers about the incidence of liposarcoma is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This creates more opportunity in the market.

Restraints/Challenges

  • Side-Effects of Soft Tissue Sarcoma Drugs

There are various side-effects associated with the soft tissue sarcoma drugs. Effects such as swelling under the skin, tummy, mouth sores, fatigue, nausea that highly disrupts the treatment market.

  • Increasing Cost Of Treatments

The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market. Increasing cost for the radiotherapy and chemotherapy may hamper the growth of soft tissue sarcoma treatment market during the forecast period.

This global soft tissue sarcoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global soft tissue sarcoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Soft Tissue Sarcoma Market Scope

The global soft tissue sarcoma market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

  • Targeted Therapy
  • Chemotherapy
  • Anti-Angiogenesis Drugs
  • Radiation Therapy
  • Others

Route of Administration

End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Soft Tissue Sarcoma Market Regional Analysis/Insights

The global soft tissue sarcoma market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global soft tissue sarcoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to the increase awareness about the diseases and rapidly disposable income.

North America dominates the market due to the increase prevalence of soft tissue sarcoma, high demand of targeted therapies and advanced healthcare facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Soft Tissue Sarcoma Market Share Analysis

The global soft tissue sarcoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global soft tissue sarcoma market

Key players operating in the global soft tissue sarcoma market include:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Lilly (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Soft Tissue Sarcoma Market is projected to grow at a CAGR of 7.9% during the forecast period by 2029.
The future market value of the Soft Tissue Sarcoma Market is expected to reach USD 6295.77 million by 2029.
The major players in the Soft Tissue Sarcoma Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), etc.
The country covered in the Soft Tissue Sarcoma Market are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials